DexCom, Inc. (NASDAQ:DXCM) has been assigned a consensus rating of “Buy” from the twenty-six ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $72.38.

DXCM has been the topic of a number of research reports. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Piper Jaffray Companies restated a “buy” rating and issued a $78.00 price target on shares of DexCom in a report on Wednesday, July 12th. BMO Capital Markets restated a “buy” rating and issued a $105.00 price target on shares of DexCom in a report on Thursday, July 13th. Cowen and Company restated a “buy” rating and issued a $90.00 price target on shares of DexCom in a report on Friday, July 14th. Finally, Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th.

In other DexCom news, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total transaction of $230,907.92. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $69.77, for a total value of $418,620.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,208 shares of company stock worth $1,597,567. Corporate insiders own 1.70% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Winslow Capital Management LLC purchased a new position in shares of DexCom in the 2nd quarter worth $117,451,000. BNP Paribas Arbitrage SA raised its position in shares of DexCom by 111.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock worth $693,000 after buying an additional 4,995 shares during the period. State Street Corp raised its position in shares of DexCom by 2.5% in the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after buying an additional 37,581 shares during the period. Macquarie Group Ltd. raised its position in shares of DexCom by 67.2% in the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after buying an additional 97,479 shares during the period. Finally, Clinton Group Inc. purchased a new position in shares of DexCom in the 2nd quarter worth $639,000.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/01/dexcom-inc-dxcm-receives-consensus-rating-of-buy-from-analysts.html.

DexCom (NASDAQ:DXCM) opened at 44.97 on Wednesday. The stock’s market cap is $3.89 billion. DexCom has a 52-week low of $42.62 and a 52-week high of $88.80. The stock has a 50 day moving average price of $54.18 and a 200 day moving average price of $67.68.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.24) EPS. On average, equities research analysts forecast that DexCom will post ($0.80) EPS for the current year.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.